The apelin receptor inhibits the angiotensin II type 1 receptor via allosteric trans-inhibition

British Journal of Pharmacology

Volumn 168, Issue 5, 2013, Pages 1104-1117

  Siddiquee, K ^a   Hampton, J ^a   McAnally, D ^a   May, L T ^b   Smith, L H ^a  

^a BURNHAM INSTITUTE   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

allosterism; angiotensin II; apelin; APJ receptor; AT1 receptor; GPCR; heterodimerization

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APELIN; APELIN RECEPTOR; BETA ARRESTIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL PHOSPHATE; RADIOLIGAND;

ALLOSTERISM; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DIMERIZATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIGAND BINDING; MOLECULAR MODEL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

ALLOSTERIC REGULATION; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CHEMISTRY TECHNIQUES, ANALYTICAL; HEK293 CELLS; HUMANS; PROTEIN MULTIMERIZATION; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84874232168     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02192.x     Document Type: Article

References (50)

1. AbdAlla S, Lother H, Abdel-tawab AM, Quitterer U, (2001). The angiotensin II AT2 receptor is an AT1 receptor antagonist. J Biol Chem 276: 39721-39726.
2. Alexander SP, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
3. Ashley E, Chun HJ, Quertermous T, (2006). Opposing cardiovascular roles for the angiotensin and apelin signaling pathways. J Mol Cell Cardiol 41: 778-781.
4. Bai M, (2004). Dimerization of G-protein-coupled receptors: roles in signal transduction. Cell Signal 16: 175-186.
5. Barki-Harrington L, Luttrell LM, Rockman HA, (2003). Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 108: 1611-1618.
6. Bouvier M, (2001). Oligomerization of G-protein-coupled transmitter receptors. Nat Rev Neurosci 2: 274-286.
7. Cheng Y, Prusoff WH, (1973). Relationship between the inhibition constant (Ki) and the concentration of an inhibitor which causes 50 per cent inhibition (Im) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
8. Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, et al. (2008). Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 118: 3343-3354.
9. Drews J, (1996). Genomic sciences and the medicine of tomorrow. Nat Biotechnol 14: 1516-1518.
10. Ellis J, Pediani JD, Canals M, Milasta S, Milligan G, (2006). Orexin-1 receptor-cannabinoid CB1 receptor heterodimerization results in both ligand-dependent and -independent coordinated alterations of receptor localization and function. J Biol Chem 281: 38812-38824.
11. George SR, Lee SP, Varghese G, Zeman PR, Seeman P, Ng GY, et al. (1998). A transmembrane domain-derived peptide inhibits D1 dopamine receptor function without affecting receptor oligomerization. J Biol Chem 273: 30244-30248.
12. George SR, Fan T, Xie Z, Tse R, Tam V, Varghese G, et al. (2000). Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem 275: 26128-26135.
13. Gines S, Hillion J, Torvinen M, Le Crom S, Casado V, Canela EI, et al. (2000). Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci U S A 97: 8606-8611.
14. Gomes I, Jordan BA, Gupta A, Rios C, Trapaidze N, Devi LA, (2001). G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med 79: 226-242.
15. Gurevich VV, Gurevich EV, (2008). How and why do GPCRs dimerize. Trends Pharmacol Sci 29: 234-240.
16. Han Y, Moreira IS, Urizar E, Weinstein H, Javitch JA, (2009). Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5: 688-695.
17. Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, et al. (2004). Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279: 26274-26279.
18. Iwanaga Y, Kihara Y, Takenaka H, Kita T, (2006). Down-regulation of cardiac apelin system in hypertrophied and failing hearts: possible role of angiotensin II-angiotensin type 1 receptor system. J Mol Cell Cardiol 41: 798-806.
19. Jordan BA, Devi LA, (1999). G-protein-coupled receptor heterodimerization modulates receptor function. Nature 399: 697-700.
20. Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, Beck P, et al. (1998). GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396: 683-687.
21. Klabunde T, Giegerich C, Evers A, (2009). Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening. J Med Chem 52: 2923-2932.
22. Kroeger KM, Pfleger KD, Eidne KA, (2003). G-protein coupled receptor oligomerization in neuroendocrine pathways. Front Neuroendocrinol 24: 254-278.
23. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, et al. (2002). Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 277: 35402-35410.
24. Lazareno S, Birdsall NJ, (1995). Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48: 362-378.
25. Maggio R, Barbier P, Colelli A, Salvadori F, Demontis G, Corsini GU, (1999). G protein-linked receptors: pharmacological evidence for the formation of heterodimers. J Pharmacol Exp Ther 291: 251-257.
26. Milligan G, Smith NJ, (2007). Allosteric modulation of heterodimeric G-protein-coupled receptors. Trends Pharmacol Sci 28: 615-620.
27. Niu W, Wu S, Zhang Y, Li W, Ji K, Gao P, et al. (2010). Validation of genetic association in apelin-AGTRL1 system with hypertension in a larger Han Chinese population. J Hypertens 28: 1854-1861.
28. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, et al. (2002). Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci U S A 99: 3294-3299.
29. Percherancier Y, Berchiche YA, Slight I, Volkmer-Engert R, Tamamura H, Fujii N, et al. (2005). Bioluminescence resonance energy transfer reveals ligand-induced conformational changes in CXCR4 homo- and heterodimers. J Biol Chem 280: 9895-9903.
30. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, et al. (2001). Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 276: 14027-14036.
31. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S, (2002). Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 277: 19762-19772.
32. Pfleger KD, Eidne KA, (2006). Illuminating insights into protein-protein interactions using bioluminescence resonance energy transfer (BRET). Nat Methods 3: 165-174.
33. Pfleger KD, Seeber RM, Eidne KA, (2006). Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nat Protoc 1: 337-345.
34. Pin JP, Kniazeff J, Liu J, Binet V, Goudet C, Rondard P, et al. (2005). Allosteric functioning of dimeric class C G-protein-coupled receptors. FEBS J 272: 2947-2955.
35. Price MR, Baillie GL, Thomas A, Stevenson LA, Easson M, Goodwin R, et al. (2005). Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68: 1484-1495.
36. Quitterer U, Lother H, Abdalla S, (2004). AT1 receptor heterodimers and angiotensin II responsiveness in preeclampsia. Semin Nephrol 24: 115-119.
37. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC, (2000a). Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288: 154-157.
38. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC, (2000b). Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 275: 7862-7869.
39. Samama P, Cotecchia S, Costa T, Lefkowitz RJ, (1993). A mutation-induced activated state of the beta 2-adrenergic receptor. Extending the ternary complex model. J Biol Chem 268: 4625-4636.
40. Siddiquee K, Hampton J, Khan S, Zadory D, Gleaves L, Vaughan DE, et al. (2011). Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 29: 724-731.
41. Smith R, McCall D, Timmermans P, (2001). Characterization of Angiotensin II Receptors. Curr Protoc Pharmacol doi: 10.1002/0471141755.ph0110s01.
42. Sohy D, Parmentier M, Springael JY, (2007). Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers. J Biol Chem 282: 30062-30069.
43. Stanasila L, Perez JB, Vogel H, Cotecchia S, (2003). Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. J Biol Chem 278: 40239-40251.
44. Sun X, Iida S, Yoshikawa A, Senbonmatsu R, Imanaka K, Maruyama K, et al. (2011). Non-activated APJ suppresses the angiotensin II type 1 receptor, whereas apelin-activated APJ acts conversely. Hypertens Res 34: 701-706.
45. Trinquet E, Bouhelal R, Dietz M, (2011). Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay. Expert Opin Drug Discov 6: 981-994.
46. Vilardaga JP, Nikolaev VO, Lorenz K, Ferrandon S, Zhuang Z, Lohse MJ, (2008). Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol 4: 126-131.
47. White JH, Wise A, Main MJ, Green A, Fraser NJ, Disney GH, et al. (1998). Heterodimerization is required for the formation of a functional GABA(B) receptor. Nature 396: 679-682.
48. Rovira X, Pin JP, Giraldo J,. (2009). The asymetric / symmertic activation of GPCR dimer as a possible mechanistic rationale for multiple signalling pathways. Trends Pharmacol Sci 31: 15-21.
49. Xu J, He J, Castleberry AM, Balasubramanian S, Lau AG, Hall RA, (2003). Heterodimerization of alpha 2A- and beta 1-adrenergic receptors. J Biol Chem 278: 10770-10777.
50. Zhong JC, Huang DY, Liu GF, Jin HY, Yang YM, Li YF, et al. (2005). Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc Res 65: 743-750.